AstraZeneca targeted drug Acalabrutinib has a new way to treat chronic lymphocytic leukemia

Share This Post

Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

The researchers believe that BTK inhibitors combined with modified CD20 antibody drugs (such as Obinutuzumab) can improve the speed and depth of Acalabrutinib treatment by responding to further sensitized cancer cells.

In the Phase 1 b / II clinical trial, the researchers evaluated the effect of the combined therapy of Acalabrutinib and Obinutuzumab at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital-Richard Research Center (OSUCCC-James), convening 45 relapsed / refractory or CLL patients who have never received treatment.

Overall, the combination therapy of Acalabrutinib and Obinutuzumab is well tolerated, and the response rate has improved over time.

Among patients who had not received any treatment, the overall response rate was 95%. The median follow-up period was 17.8 months. The overall survival rate (OS) of patients with relapsed / refractory CLL was 92%, with a median follow-up period of 21 months.

OSUCCC-James. Associate Professor and first author Jennifer Woyach said that despite the progress made in the treatment of CLL in recent years, the need for additional treatment options is still urgent.

The overall effectiveness of the Acalabrutinib trial emphasizes that this clinical study may have a potential impact on the management of CLL.

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code